Search Results

You are looking at 181 - 190 of 529 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Receipt of Guideline-Concordant Care Does Not Explain Breast Cancer Mortality Disparities by Race in Metropolitan Atlanta

Lindsay J. Collin, Ming Yan, Renjian Jiang, Keerthi Gogineni, Preeti Subhedar, Kevin C. Ward, Jeffrey M. Switchenko, Joseph Lipscomb, Jasmine Miller-Kleinhenz, Mylin A. Torres, Jolinta Lin, and Lauren E. McCullough

to racial disparities in breast cancer mortality. Early investigations (circa 1990–2005) have reported that minority women are less likely to receive appropriate adjuvant therapy, although findings appear to be mixed and few studies report survival

Full access

Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study

Tara B. Sanft, Jenna Wong, Brandon O’Neal, Natalia Siuliukina, Rachel C. Jankowitz, Mark D. Pegram, Jenny R. Fox, Yi Zhang, Kai Treuner, and Joyce A. O’Shaughnessy

letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage . N Engl J Med 2003 ; 349 : 1793 – 1802 . 6. Jakesz R , Greil R , Gnant M , Extended adjuvant therapy with anastrozole among postmenopausal breast cancer

Full access

NCCN News

imaging specialists, and pulmonologists. “Radiation is recommended as an adjuvant therapy to improve local control after surgery, and it is also an effective palliative treatment for relief of chest pain that is often associated with mesothelioma,” said

Full access

NCCN News

.” Approximately half of patients with metastatic melanoma harbor an activating mutation of BRAF, a signaling kinase. These patients tend to show dramatic responses to vemurafenib. Other updates include expanded recommendations on adjuvant therapy and radiation

Full access

NCCN News

Cancer Center, “A Randomized Phase II Study Comparing Concise versus Prolonged Afatinib as Adjuvant Therapy for Stage I–III NSCLC with EGFR Mutation” The awardees responded to a request for proposals issued by the NCCN ORP to the 21 NCCN Member

Full access

Renaming Ductal Carcinoma in Situ: Would Removing “Carcinoma” Reduce Overtreatment?

Sara H. Javid, L. Christine Fang, Larissa Korde, and Benjamin O. Anderson

34%, 1 , 3 a favorable outcome that has been attributed to the combination of increased screening mammography and improved adjuvant therapy. 4 However, despite the steady increase in DCIS detection and treatment in the 1990s, the subsequent

Full access

Ten Years of Progress Against Breast Cancer: A Partnership of Basic and Clinical/Translational Science

Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel

-free and overall survival. 7 The effectiveness of aromatase inhibitors in the treatment of metastatic breast cancer led to a number of trials incorporating them into the adjuvant therapy of postmenopausal women with early-stage hormone receptor

Full access

Neoadjuvant Radiotherapy Use in Locally Advanced Rectal Cancer at NCCN Member Institutions

Marsha Reyngold, Joyce Niland, Anna ter Veer, Dana Milne, Tanios Bekaii-Saab, Steven J. Cohen, Lily Lai, Deborah Schrag, John M. Skibber, William Small Jr, Martin Weiser, Neal Wilkinson, and Karyn A. Goodman

adjuvant therapy data (n=3). A total of 29 patients received postoperative RT and were excluded from the analysis of factors associated with omission of preoperative RT. The minimum follow-up time was 120 days for all patients. Variables Analyzed

Full access

Progress in the Management of Melanoma in 2013

Daniel G. Coit and Anthony J. Olszanski

considered at high risk for recurrence after adjuvant therapy, interferon-alfa appears to confer a small benefit. The value of high-dose interferon was first established in 1996 by Kirkwood et al. 5 for patients with T4 lesions or evidence of regional

Full access

Treatment of Early-Stage Esophageal Adenocarcinoma

Ariel Polish and Mary F. Mulcahy

neoadjuvant or adjuvant therapy. One retrospective study focused on 49 patients with adenocarcinoma (90%) or squamous (10%) cancer of the esophagus who were staged as T2,N0,M0 and received neoadjuvant chemoradiation. 14 The study found that the 5-year rates